RaQualia Pharma Inc. (JP:4579)
:4579
Want to see JP:4579 full AI Analyst Report?
Top Page
RaQualia Pharma Inc.
(4579)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥485.00
▼(-51.98% Downside)
Action:Reiterated
Date:05/21/26
The score is held down primarily by very weak technical indicators (price below key moving averages, negative MACD, and extremely oversold RSI/Stoch) and volatile cash-flow history. Financial performance is modestly supportive due to strong margins and moderate leverage, while valuation is penalized by a negative P/E and lack of dividend yield data.
Positive Factors
High gross & EBITDA margins
Sustained high gross margins (~76.9%) and positive EBITDA (~23.5%) reflect durable IP-driven economics and efficient product-level profitability. These margins support ongoing R&D funding and make licensing deals more attractive, improving long-term ability to finance pipeline advancement without constant dilution.
Negative Factors
Inconsistent cash generation
Volatile cash generation—positive TTM OCF/FCF but negative results in 2025 and prior large outflows—reduces the firm's ability to reliably self-fund clinical programs. This unpredictability heightens financing risk, potentially forcing more dilutive raises or dependence on partner milestones over multi-quarter horizons.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross & EBITDA margins
Sustained high gross margins (~76.9%) and positive EBITDA (~23.5%) reflect durable IP-driven economics and efficient product-level profitability. These margins support ongoing R&D funding and make licensing deals more attractive, improving long-term ability to finance pipeline advancement without constant dilution.
Read all positive factors
RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥11.98B
Dividend YieldN/A
Average Volume (3M)352.93K
Price to Earnings (P/E)237.7
Beta (1Y)0.90
Revenue Growth11.45%
EPS GrowthN/A
CountryJP
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.96
Shares Outstanding24,458,673
10 Day Avg. Volume795,170
30 Day Avg. Volume352,926
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
RaQualia Pharma Inc. Business Overview & Revenue Model
Company Description
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and ...
How the Company Makes Money
RaQualia Pharma’s revenue model is primarily based on monetizing its drug discovery and development pipeline through out-licensing/partnering arrangements. In practice, the company seeks to generate earnings by (1) receiving upfront payments when ...
RaQualia Pharma Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.82B | 3.98B | 3.11B | 1.90B | 2.92B | 2.78B |
| Gross Profit | 2.94B | 3.27B | 2.48B | 1.66B | 2.69B | 2.46B |
| EBITDA | 725.55M | 971.88M | 188.27M | -111.80M | 1.00B | 1.02B |
| Net Income | 52.64M | 273.12M | -495.03M | -323.66M | 723.39M | 755.79M |
Balance Sheet | ||||||
| Total Assets | 11.39B | 10.51B | 9.66B | 6.93B | 6.26B | 5.23B |
| Cash, Cash Equivalents and Short-Term Investments | 4.49B | 3.24B | 3.34B | 3.76B | 3.93B | 2.66B |
| Total Debt | 2.79B | 2.90B | 3.45B | 432.02M | 222.34M | 39.07M |
| Total Liabilities | 3.30B | 3.62B | 4.08B | 809.83M | 760.67M | 446.19M |
| Stockholders Equity | 8.09B | 6.90B | 5.57B | 6.12B | 5.50B | 4.79B |
Cash Flow | ||||||
| Free Cash Flow | 134.81M | -423.98M | 84.24M | -940.80M | 1.45B | 260.61M |
| Operating Cash Flow | 200.97M | -356.63M | 180.94M | -718.60M | 1.48B | 366.03M |
| Investing Cash Flow | -144.39M | 124.32M | -3.67B | -135.37M | -47.65M | -279.25M |
| Financing Cash Flow | 1.83B | 380.26M | 2.98B | 793.45M | -29.56M | -16.44M |
RaQualia Pharma Inc. Technical Analysis
Negative
1010.00
Price Trends
728.36
Negative
857.90
Negative
783.45
Negative
Market Momentum
-78.57
Positive
25.08
Positive
13.71
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Negative. The current price of 1010 is above the 20-day moving average (MA) of 592.05, above the 50-day MA of 728.36, and above the 200-day MA of 783.45, indicating a bearish trend. The MACD of -78.57 indicates Positive momentum. The RSI at 25.08 is Positive, neither overbought nor oversold. The STOCH value of 13.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4579.
RaQualia Pharma Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥11.98B | 237.68 | ― | ― | 11.45% | ― | |
47 Neutral | ¥18.75B | -3.75 | -184.71% | ― | 29.94% | 86.03% | |
47 Neutral | ¥92.09B | -9.03 | -19.31% | ― | 10.88% | -327.56% | |
47 Neutral | ¥76.51B | -46.08 | ― | ― | 0.80% | 32.87% | |
46 Neutral | ¥133.79B | -37.29 | -10.16% | ― | -59.19% | -124.16% | |
45 Neutral | ¥8.57B | -8.41 | -26.70% | ― | 60.80% | -8.89% |
* Healthcare Sector Average
JP:4579
RaQualia Pharma Inc.
490.00
-153.00
-23.79%
JP:4563
AnGes
47.00
-24.00
-33.80%
JP:4587
Peptidream
1,030.50
-685.00
-39.93%
JP:4565
Sosei Group
996.00
49.00
5.17%
JP:4571
NanoCarrier Co., Ltd.
103.00
-24.00
-18.90%
JP:4588
Oncolys BioPharma, Inc.
2,614.00
1,975.00
309.08%
RaQualia Pharma Inc. Corporate Events
RaQualia Pharma Swings to Quarterly Loss but Projects Full-Year Recovery
May 15, 2026
RaQualia Pharma reported first-quarter 2026 consolidated net sales of ¥801 million, down 16.9% year on year, and swung to an operating loss of ¥160 million and a net loss of ¥225 million, reflecting weaker sales and higher costs. De...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.